Caspase-independent pathway of amyloid-beta cytotoxicity

Alexei Degterev, PhD
Harvard Medical School (Boston, MA)
Year Awarded:
2003
Grant Duration:
April 1, 2003 to March 31, 2005
Disease:
Alzheimer's Disease
Award Amount:
$100,000
Grant Reference ID:
A2003223
Award Type:
Standard
Award Region:
US Northeastern

Caspase-independent pathway of amyloid-beta cytotoxicity

Details


Neuronal loss induced by oligomerized amyloid beta (Aß) peptide is an important feature of Alzheimer's disease. It has been proposed that apoptotic cell death, the body's own suicide program to ensure the elimination of dangerous cells, may contribute to the neuronal loss in AD. However, the inhibition of caspases, a family of proteases that execute apoptosis, only partially relieves the cytotoxicity induced by AD, which suggests that other, caspase-independent cell death pathways must exist. In previous work, Dr. Degterev defined a novel caspase-independent cell death pathway named “aponecrosis.” He identified two inhibitors (ANI1 and ANI2) that specifically inhibit aponecrosis in a number of cell types. The major goal of this study is to identify the molecular mechanism of the aponecrotic pathway induced by Aß in vitro and to define its role in animal models of AD. Ultimately, this work could lead to the identification of novel molecular targets for drug interventions in AD, and ANIs may serve as potential prototypes and/or target compounds in the development of new AD treatments.

Publications

Degterev, A., Huang, Z., Boyce, M., Li, Y., Mizushima, N., Cuny, G.D., Mitchison,T.J., Moskowitz, M.A., and Yuan, J. (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nature Chemical Biology. 1(2):112-9.  

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.